---
title: "Agomab Therapeutics director Naimish Patel files initial beneficial ownership statement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299091117.md"
description: "Agomab Therapeutics filed an initial Form 3 with the SEC, naming director Naimish Patel. This filing marks Patel's entry into SEC insider reporting requirements for beneficial ownership."
datetime: "2026-09-15T20:06:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299091117.md)
  - [en](https://longbridge.com/en/news/299091117.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299091117.md)
generator: "portal-rs"
---

# Agomab Therapeutics director Naimish Patel files initial beneficial ownership statement

-   Agomab Therapeutics filed an initial Form 3 naming Naimish Patel as a director, marking his entry into SEC insider reporting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-107912), on September 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [AGMB.US](https://longbridge.com/en/quote/AGMB.US.md)

## Related News & Research

- [AGMB: Ontunisertib showed sustained safety and disease control in FSCD, supporting Phase 2b initiation](https://longbridge.com/en/news/300671409.md)
- [Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial](https://longbridge.com/en/news/300717682.md)
- [Nebius COO Nave Ophir disposes of USD 113.38 million in Class A shares](https://longbridge.com/en/news/301073075.md)
- [Personalis-Tempus AI deal clears US antitrust waiting period under HSR Act](https://longbridge.com/en/news/301072040.md)
- [History Says Infrastructure Booms Create Winners and Losers. Here Are 3 AI Cloud Stocks to Watch.](https://longbridge.com/en/news/301060298.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**